<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01702324</url>
  </required_header>
  <id_info>
    <org_study_id>DD-25</org_study_id>
    <secondary_id>0290-12-TLV</secondary_id>
    <nct_id>NCT01702324</nct_id>
  </id_info>
  <brief_title>Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study</brief_title>
  <official_title>Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fortuderm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fortuderm Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of DD-25, a new topical drug, on
      plaque Psoriasis Vulgaris.

      The study will include subjects at plaque stage from 5-20% body area involvement. A total of
      30 subjects will be treated with cream application on affected areas twice daily for three
      weeks.The efficacy of the preparation will be documented by PASI score, Global physician
      assessment and photos.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis Vulgaris remains a widespread clinical entity with chronic outflares and various
      regimens of treatment, none of them definitive. A new safe and efficacious, external
      treatment is required for.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy after 3 weeks as compared to baseline.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Evaluation of the effectiveness of DD-25 over a period of 3 weeks treatment by analyzing the changes in the Psoriasis Area &amp; Severity Index (PASI) in moderate to mild Plaque Psoriasis patients. Improvement to be assessed by changes in erythema, induration and desquamation as seen on days 0, 10 and 21.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PASI reduction of 50%</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>DD-25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A concentration of 0.025% of topical DD-25 cream.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DD-25</intervention_name>
    <description>A topical DD-25 cream at 0.025% concentration.</description>
    <arm_group_label>DD-25</arm_group_label>
    <other_name>Fortuderm DD-25 Psoriasis Cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject age 18-60

          2. Diagnosis of PS by a dermatologist with lesions on arms, legs or trunk

          3. Subjects have stable plaque PS, mild to moderate form, Body Surface Area of 5-20%.

          4. Subject understood and signed an informed consent form

        Exclusion Criteria:

          1. Guttate, erythrodermic, palm-plantar or pustular psoriasis as sole or predominant form
             of psoriasis.

          2. Hypersensitivity to sunlight; history of Lupus, PMLE, or any disease known to be
             worsened by UV light exposure

          3. Pregnancy, breast feeding

          4. History of cancer, excluding non-melanoma skin cancer.

          5. Patients with history of ischemic heart disease (e.g. angina pectoris, myocardial
             infarction); cerebrovascular syndromes, peripheral vascular or uncontrolled
             hypertension. Subjects with known severe hepatic and/or severe renal insufficiency.

          6. Any medical condition that, in the opinion of the Investigator, would jeopardize the
             health of the patient during the course of this study.

          7. Systemic treatment with biological therapies with a possible effect on psoriasis
             vulgaris within 4 months or 5 drug half-lives prior to checkup.

          8. Systemic treatments with all other therapies than biologicals, with a potential effect
             on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids,
             immuno-suppressants) within the 8-week period prior to randomization. Subjects using
             within the 8 week period prior to randomization PUVA or Phototherapy. Use of SSRI or
             MAO inhibitors.

          9. Subjects using one of the following TOPICAL drugs for the treatment of PS within 2
             weeks prior to randomization: e.g. WHO group I-II corticosteroids, retinoids, Vit. D
             analogues, immunomodulators, Anthracene derivatives, Salicylic acid.

         10. Subjects with current participation in any other interventional clinical or subjects
             with any concomitant dermatological disorder(s) which might preclude accurate
             evaluation of the psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagit Matz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Dermatology, Tel Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avi Dascalu, M.D., Ph.D.</last_name>
    <phone>972-3-6099005</phone>
    <email>dasc01@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dvora Krulfeld, M.A.</last_name>
      <phone>97236973768</phone>
      <email>dvoray@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Hagit Matz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2012</study_first_submitted>
  <study_first_submitted_qc>October 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2012</study_first_posted>
  <last_update_submitted>October 4, 2012</last_update_submitted>
  <last_update_submitted_qc>October 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis Vulgaris</keyword>
  <keyword>Plaque</keyword>
  <keyword>Topical</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

